Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
A phase 1/2 trial of Pembrolizumab in metastatic cancer, run by Qurient Co., Ltd., now recruiting.
Overview
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05394103 by Qurient Co., Ltd., with 130 participants planned, started 2022-08-30 and due to reach its primary completion in 2025-12-30. Interventions recorded: Q901, KEYTRUDA® (pembrolizumab). Conditions listed: Advanced Cancer, Metastatic Cancer. No results are recorded here; the registry entry is the source.
Setting
A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901Administered Via Intravenous Infusion as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Selected Advanced Solid Tumors With Cohort Expansions at the Recommended Phase 2 Dose
Phase
Phase 1/2
Sponsor
Qurient Co., Ltd.
Registry
Enrolled
130